Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer/Radiotherapie is Scopus-indexed (Q2, CiteScore 3.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Masson s.r.l..
Checked against the index lists dated .
ISSN 1278-3218Verify ISSN ↗1769-6658Verify ISSN ↗
Publisher: Elsevier Masson s.r.l.
Cost to publish: About US$2,190 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 176 / 361 | 51st | Q2 |
| Oncology | 259 / 428 | 39th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1997–present, best quartile Q2, CiteScore 3.1.
Cancer/Radiotherapie is Q2 in Radiology, Nuclear Medicine and Imaging (rank 176 of 361) and Q3 in Oncology (rank 259 of 428), by CiteScore 2025.
Cancer/Radiotherapie is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.1, which places it in quartile Q2 at the 51st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.481, quartile Q2, with an H-index of 40.
The publisher lists an article processing charge of about US$2,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer/Radiotherapie is published by Elsevier Masson s.r.l. Its print ISSN is 1278-3218 and its online ISSN is 1769-6658.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer/Radiotherapie has an h-index of 53 and a 2-year mean of 1.51 citations per paper (OpenAlex). Its Scopus CiteScore is 3.1, quartile Q2. On 2-year citations it ranks #157 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Cancer/Radiotherapie published 114 papers in 2025; its busiest recent year was 2017 with 276. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 90 research articles (2025–2026), authors are most often from France (86.8%), Belgium (2.4%) and India (2.2%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.